Who we are
Orthogen AG is a privately held research-based biotech company, founded in Düsseldorf, Germany. We have been developing patented medical platform technologies for targeted therapies engaging autologous and regenerative medicine. These proprietary applications span various research fields, including orthopedics, veterinary medicine and aesthetics.
>25
years
of research in molecular and autologoous medicine
>400.000
treatments
with the help of our platform technologies worldwide
130
scientific publications & academic theses
about our approaches in international scientific journals or universities
Our Mission
At Orthogen, our mission is to discover, develop and deliver novel therapies, based on autologous technologies. These can address major unmet needs in chronic diseases related to biomolecular changes including inflammation, oxidative stress and diminished regenerative potential. Our goal is to treat the underlying disease mechanisms together with symptoms.
For the purpose of research, we successfully worked or cooperated with the following institutions amongst others:







Dedicated to research, we strive for new approaches with the anticipation to alter the course of medicine and deliver concrete solutions in the best interest of the patient.
Peter Wehling, MD, PhD
CEO and Founder of Orthogen AG